Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +62.14% and +25.22%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?